CORE Biomedicine's $21M Bet on Cancer's Biological Identity

BOSTON and TOKYO – July 28, 2026

In a move that signals a significant shift in oncology, CORE Biomedicine has secured a formidable $21 million in Series A financing, coupled with a prestigious grant from the Japan Agency for Medical Research and Development (AMED). This infusion of capital is not just another funding announcement; it's a powerful endorsement of a strategy that aims to attack cancer at its very foundation, moving beyond the well-trodden path of genomics to target the fundamental "lineage" that defines a cancer cell's identity.

Beyond the Genome: The Promise of Lineage-Based Oncology

For the past two decades, precision oncology has been largely synonymous with genomics. The model was straightforward: sequence a tumor, find a genetic mutation, and match it to a targeted drug. While this has produced life-saving therapies, its limitations are becoming increasingly apparent. Many cancers lack an "actionable" mutation, and others quickly develop resistance, leaving patients and clinicians searching for new options.

CORE Biomedicine is pioneering a different path. Their lineage-based approach focuses on the core biological pathways that dictate a cell's identity and drive its malignant behavior. Instead of just targeting a single mutated gene, the goal is to dismantle the very biological machinery that allows a cancer cell to exist and proliferate. This strategy is born from a deeper understanding of cancer biology, recognizing that a cell's developmental origin—its lineage—is a critical dependency that can be exploited.

"CORE Biomedicine's lineage-based approach addresses a fundamental challenge in cancer biology that genomics alone cannot solve," said Dr. Makoto (Mark) Ohori, Partner and Chief Investment Officer for Life Sciences at UTokyo Innovation Platform Co., Ltd., which co-led the financing round.

This method holds the potential to unlock treatments for a much broader patient population. By targeting pathways conserved across tumors with different genetic profiles, these therapies could be effective where genomics-based drugs fall short. Theoretically, by attacking the foundational programming of a cancer cell, these treatments could also produce more durable responses and make it harder for resistance to emerge. The technical hurdles are significant, requiring the identification of true lineage dependencies and the design of highly selective drugs, but the potential payoff is a paradigm shift in how we treat cancer.

A Global Vote of Confidence: The Strategic Funding Structure

The $21 million Series A round is a masterclass in strategic capital formation. Co-led by UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) and Elikon Venture, the syndicate includes a diverse group of investors from Japan and China, including InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., and Suzhou Capital Group Co., Ltd. This isn't just about money; it’s about building a global operational ecosystem.

UTokyo IPC, the venture arm of the prestigious University of Tokyo, provides deep connections to Japan's premier academic and research institutions. Elikon Venture, a global biotech investor, specializes in connecting its portfolio companies to China's vast industrial resources. An executive from Elikon Venture expressed high praise for the team, stating they "highly recognize the CORE Biomedicine team for their distinctive insights and extensive R&D experience in oncology area."

Further bolstering this financial foundation is a highly competitive grant from AMED, Japan's equivalent of the NIH. The grant falls under the "Strengthening Program for Pharmaceutical Startup Ecosystem," a multi-billion-dollar government initiative designed to supercharge Japan's biopharma sector. This program provides non-dilutive funding to promising startups, often matching or even doubling the investment from registered venture capital firms like UTokyo IPC. For CORE Biomedicine Japan, the company's wholly-owned subsidiary, this grant not only provides crucial R&D funds but also deeply embeds the company within Japan's network of universities, hospitals, and biopharma leaders. This dual mechanism of venture financing and government support represents a powerful validation of both the science and the business strategy.

From Lab to Clinic: A Veteran Team Charts the Course

With this substantial war chest, CORE Biomedicine is poised to accelerate its lead programs from the discovery phase toward the clinic. "This venture financing and AMED's support represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines," said Dr. Ping Zhu, Co-Founder and CEO of the company.

The team's confidence is rooted in deep industry experience. CORE was founded by former leaders of H3 Biomedicine, an Eisai-owned biotech known for its work in precision oncology. Dr. Zhu, who previously served as President and Chief Scientific Officer at H3, has a track record of advancing novel compounds into clinical trials. He is joined by a seasoned executive team, including co-founder Dr. Guozhu Zheng, with decades of R&D experience, and a Head of Clinical Development, Dr. Sahmoud, with leadership experience from Celgene and Novartis. This scientific and clinical pedigree is precisely what gives investors the confidence to back such an ambitious scientific vision.

While the company remains in the preclinical stage, it is advancing a portfolio of innovative programs. Dr. Zhu has previously indicated that the lead program, targeting urothelial and gastrointestinal cancers, could enter clinical trials as early as 2026. This timeline demonstrates a clear intent to rapidly translate their foundational science into tangible therapies for patients.

A New Blueprint for Biotech Innovation

CORE Biomedicine's strategy offers a compelling blueprint for the next industrial revolution in biotechnology. The innovation here isn't confined to the laboratory; it's embedded in the very structure of the company. By establishing a global footprint with operational hubs in the US (Boston), Japan (Tokyo), and China (Suzhou), the company is leveraging a systems-based approach to mitigate risk and maximize opportunity.

This model taps into the world's leading innovation hubs for what they do best: cutting-edge science and R&D leadership from the Boston biotech cluster, strategic, long-term capital and academic collaboration from Japan, and market access and industrial scale from China. It is a departure from the traditional, single-country startup model, representing a more resilient and globally integrated way to navigate the long and capital-intensive journey of drug development. For leaders watching the disruption of traditional industries, CORE Biomedicine provides a powerful case study in how novel manufacturing and strategic global partnerships are becoming the essential tools for success.